Current treatments for TB use a one-size-fits-all approach and usually lasts for at least six months. Shortening the standard treatment of TB could help reduce drug resistance and disease burden in developing countries.
Previous attempts to shorten treatment duration, usually to four months, have been unsuccessful when compared with six-month treatments. While six-month courses cure 95% of patients, shorter courses only cure 80-85%. If scientists were able to identify the patients who only require four-month therapy before starting treatment, treatment duration could be reduced in most patients, even with present drugs.
PredictTB will enrol and follow-up 620 patients with drug-sensitive pulmonary TB in a clinical trial to validate candidate biomarkers as well as identify and evaluate new, improved criteria that can identify patients who can be cured with shorter treatment.
Using Biomarkers to Predict TB Treatment Duration
EDCTP, BMGF, NIH, Grand Challenges China, ICIDR, RePORT South Africa
1 February 2017 – 31 July 2022 (66 months)
20 million EUR
Prof Gerhard Walzl, Stellenbosch University, South Africa (EDCTP) and Dr Clifton Barry, III, PhD, National Institute of Allergy and Infectious Diseases, US (BMGF & NIH)
17 partners from Africa, Europe, North America, and China.